TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.

Martin H Voss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.